Post Profile

Critical Path for Parkinson's Consortium achieves EMA support

(The Critical Path Institute (C-Path)) The Critical Path Institute, in partnership with Parkinson's UK, announce the European Medicines Agency has issued a biomarker letter of support for Parkinson's disease. EMA is recommending the use of neuroimaging biomarker dopamine transporter imaging as an exploratory biomarker for early PD. The letter was issued to the Critical Path for Parkinson's Consortium, in response to the consortium's submission of data supporting the use of the biomarker.
read more


Related Posts

National NIH Collaboration To Find Parkinson's Biomarkers And Open Vast Data Sharing Opportunities

Health : Medical News Today

Last month, the National Institutes of Health announced a new collaborative initiative that aims to accelerate the search for biomarkers -- changes in the body that can be used to predict, diagnose or monitor a disease -- in Parkins...

EMEA Releases Guidelines On Development Of Medicines For Alzheimer's Disease And Parkinson's Disease

Health : Medical News Today

The European Medicines Agency (EMEA) has released two guidelines for companies developing medicines for the treatment of Alzheimer's disease and other dementias, and for Parkinson's disease, in the light of recent scientific progres...

New Study Finds FDA Approval Process For Cancer Drugs Faster Than The European Medicines Agency (EMA)

Health : Medical News Today

The US Food and Drug Administration (FDA) is often criticized as inefficient compared to its European counterpart, the European Medicines Agency (EMA), particularly in the field of oncology. However, a new study appearing in Health ...

European Scientific Committee Positive Recommendation From For A New Once Daily Mirapexin(R) Formulation For The Treatment Of Parkinson's Disease

Health : Medical News Today

Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin®...

IMI SAFE-T and C-Path PSTc obtain regulatory support for new liver safety biomarkers

Academics / Chemistry : EurekAlert: Chemistry

(The Critical Path Institute (C-Path)) IMI's SAFE-T (Safer and Faster Evidence Based Translation) Consortium and C-Path's Predictive Safety Testing Consortium (PSTC) announced today that FDA and EMA issued Letters of Support for new...


Copyright © 2016 Regator, LLC